Cancer vaccines

Worldwide Human Papillomavirus (HPV) Vaccines Overview 2020 - Pipeline & Marketed Vaccines, Regulatory Events, Clinical Trial Landscape, Future Trends, KOL Insights, Unmet Needs, Sales (2015-2024)

Thursday, June 18, 2020 - 9:30pm

DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 18, 2020 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Wednesday, June 17, 2020 - 3:00pm

Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.

Key Points: 
  • Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.
  • In this project, dendritic cell cancer vaccines will be generated in Saint-Gobains VueLife C Series FEP bags.
  • View the full release here: https://www.businesswire.com/news/home/20200617005121/en/
    Interdisciplinary partnership between Saint-Gobain, Kanyr Pharma, and McGill in the development of optimized culture environments for dendritic cell cancer vaccines.
  • The ImmunyrTM technology was developed by Kanyr Pharma to activate each patients own immune system to target several types of cancer.

2020 Disease Analysis Report: Human Papillomavirus (HPV) Vaccines - ResearchAndMarkets.com

Monday, June 15, 2020 - 12:11pm

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers

Friday, June 12, 2020 - 11:40pm

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.

Key Points: 
  • The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
  • Todays approval for the prevention of HPV-related oropharyngeal and other head and neck cancers represents an important step in Mercks mission to help reduce the number of men and women affected by certain HPV-related cancers.
  • But, for those who don't clear the virus, it can cause certain cancers.
  • GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a healthcare provider.

Global Neoantigen Cancer Vaccines Market to Exhibit a CAGR of ~35% During 2020-2025

Tuesday, June 9, 2020 - 3:00pm

The Global Neoantigen Cancer Vaccine Market is projected to grow at a CAGR of close to 35% during the forecast period.

Key Points: 
  • The Global Neoantigen Cancer Vaccine Market is projected to grow at a CAGR of close to 35% during the forecast period.
  • The key factor responsible for the growth of the neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in the healthcare sector.
  • The market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region and company.
  • Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well.

Global Neoantigen Cancer Vaccine Market Review, Assessment and Forecast 2015-2025 - ResearchAndMarkets.com

Monday, June 8, 2020 - 12:04pm

The "Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
  • The Global Neoantigen Cancer Vaccine Market is projected to grow at a CAGR of close to 35% during the forecast period.
  • The key factor responsible for the growth of the neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in the healthcare sector.
  • Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well.

Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors

Monday, June 1, 2020 - 10:46am

Data described in the publication demonstrate that SYNB1891 treatment cleared tumors and stimulated antitumor immunity in preclinical models of cancer.

Key Points: 
  • Data described in the publication demonstrate that SYNB1891 treatment cleared tumors and stimulated antitumor immunity in preclinical models of cancer.
  • "The targeted delivery and dual immune stimulatory activity of SYNB1891 offer distinct advantages over other approaches," said Aoife Brennan, M.B., Ch.
  • "The preclinical data published today highlight the transformative potential of SYNB1891.
  • The publication titled, "Immunotherapy with an engineered bacteria by targeting the STING pathway for anti-tumor immunity," details the engineering and characterization of SYNB1891.

Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Friday, May 15, 2020 - 6:10am

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System.
  • For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu

Genocea to Present Long-term Follow-up Data from GEN-009 Neoantigen Vaccine at Virtual ASCO 2020

Wednesday, May 13, 2020 - 11:02pm

Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.

Key Points: 
  • Seven out of the eight patients enrolled have continued without progression with a median follow up of over one year.
  • No significant adverse side effects were reported with the administration of GEN-009, with only mild symptoms associated with the vaccine adjuvant.
  • Title: GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
  • Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time.

Achilles Therapeutics announces formation of Scientific Advisory Board

Wednesday, May 13, 2020 - 12:00pm

The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.

Key Points: 
  • The SAB will work closely with Achilles senior management team and Founders to advance the Companys pipeline of solid tumor cancer therapies.
  • We are delighted to be working with world-renowned experts who bring deep scientific and medical expertise as we develop the next-generation of truly patient-specific clonal-neoantigen therapies that will harness the immune system to destroy cancer cells, said Dr Iraj Ali, CEO of Achilles Therapeutics.
  • Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.
  • Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.